UWM
INO icon

Urban Wealth Management’s Inovio Pharmaceuticals INO Stock Holding History

Urban Wealth Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$0 Buy
+17
New +$479 ﹤0.01% 354

Other funds holding INO

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Urban Wealth Management's INO Position: Q2 2022 in Review

Urban Wealth Management opened a new position in Inovio Pharmaceuticals (INO) in Q2 2022: 17 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #354 among its holdings.

184 funds tracked by Wall St. Rank hold INO as of Q2 2022.

  • Urban Wealth Management held 17 shares of Inovio Pharmaceuticals worth $0 as of Q2 2022.
  • Inovio Pharmaceuticals was a new Urban Wealth Management position in Q2 2022.
  • Inovio Pharmaceuticals made up ﹤0.01% of Urban Wealth Management's portfolio in Q2 2022, its #354 holding.
  • 184 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2022.

Based on Urban Wealth Management's 13F filing for Q2 2022, filed 22 Jul 2022.